Akeso Announces the Completion of Patient Enrollment in the Phase III Clinical Trial (HARMONi-6) Comparing Ivonescimab and Tislelizumab for First-Line Treatment of Sq-NSCLC
HONG KONG, Feb. 6, 2025 /PRNewswire/ — Akeso, Inc. (9926.HK) ("Akeso" or the…